Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2025

1.

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Smith TJ, Loprinzi CL, Deville C.

N Engl J Med. 2018 May 3;378(18):1745-1746. doi: 10.1056/NEJMc1801992. No abstract available.

2.

[Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].

de la Taille A, Mardoyan S, Lafaye A.

Prog Urol. 2018 Jan;28(1):32-38. doi: 10.1016/j.purol.2017.10.004. Epub 2017 Dec 7. French.

PMID:
29223415
4.

Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate.

Hannah-Shmouni F, Moraitis AG, Romero VV, Faucz FR, Mastroyannis SA, Berthon A, Failor RA, Merino M, Demidowich AP, Stratakis CA.

Horm Metab Res. 2018 Feb;50(2):124-132. doi: 10.1055/s-0043-122074. Epub 2017 Nov 28.

PMID:
29183089
5.

Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.

Hammerer PG, Wirth MP; ENA E005/DE-N-LEU-019 study group.

Urol Int. 2018;100(1):72-78. doi: 10.1159/000479434. Epub 2017 Nov 25.

PMID:
29183006
6.

Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.

Leschek EW, Flor AC, Bryant JC, Jones JV, Barnes KM, Cutler GB Jr.

J Pediatr. 2017 Nov;190:229-235. doi: 10.1016/j.jpeds.2017.07.047.

PMID:
29144249
7.

Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome

Kasum M, Orešković S, Franulić D, Čehić E, Lila A, Vujić G, Grgić F.

Acta Clin Croat. 2017 Mar;56(1):133-142. doi: 10.20471/acc.2017.56.01.19. Review.

PMID:
29120551
8.

High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer.

Barash OO, Hinckley MD, Rosenbluth EM, Ivani KA, Weckstein LN.

Hum Reprod. 2017 Nov 1;32(11):2209-2217. doi: 10.1093/humrep/dex299.

PMID:
29040519
9.

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.

Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL, Van Den Eeden SK, Potosky AL.

Br J Cancer. 2017 Oct 10;117(8):1233-1240. doi: 10.1038/bjc.2017.280. Epub 2017 Aug 24.

PMID:
29017178
10.

Improved final predicted height with the injection of leuprolide in children with earlier puberty: A retrospective cohort study.

Lin YC, Lin CY, Chee SY, Yen HR, Tsai FJ, Chen CY, Wang CH.

PLoS One. 2017 Oct 3;12(10):e0185080. doi: 10.1371/journal.pone.0185080. eCollection 2017.

11.

Cutaneous granulomas caused by subcutaneous injections of leuprorelin acetate.

Kluger N, Hahtola S, Lempinen T, Jeskanen L.

Presse Med. 2017 Oct;46(10):966-968. doi: 10.1016/j.lpm.2017.08.004. Epub 2017 Sep 14. No abstract available.

PMID:
28919272
12.

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.

Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H.

Clin Cancer Res. 2017 Nov 15;23(22):6812-6822. doi: 10.1158/1078-0432.CCR-17-0807. Epub 2017 Sep 11.

PMID:
28893901
13.

The in vivo transformation and pharmacokinetic properties of a liquid crystalline drug delivery system.

Otte A, Báez-Santos YM, Mun EA, Soh BK, Lee YN, Park K.

Int J Pharm. 2017 Oct 30;532(1):345-351. doi: 10.1016/j.ijpharm.2017.08.098. Epub 2017 Aug 24.

PMID:
28844902
14.

Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations.

Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Kurebayashi J.

J Med Econ. 2017 Nov;20(11):1163-1169. doi: 10.1080/13696998.2017.1364647. Epub 2017 Aug 16.

PMID:
28782387
15.

Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study.

Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, Inagaki T, Banno H, Sobue G.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1026-1032. doi: 10.1136/jnnp-2017-316015. Epub 2017 Aug 5.

PMID:
28780536
16.

Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.

Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Oya M.

J Med Econ. 2017 Nov;20(11):1155-1162. doi: 10.1080/13696998.2017.1362410. Epub 2017 Aug 16.

PMID:
28758810
17.

Progesterone receptor modulators for endometriosis.

Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, Huang W.

Cochrane Database Syst Rev. 2017 Jul 25;7:CD009881. doi: 10.1002/14651858.CD009881.pub2. Review.

PMID:
28742263
18.

Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.

Tanios G, Mungo NA, Kapila A, Bajaj K.

BMJ Case Rep. 2017 Jul 14;2017. pii: bcr-2016-218514. doi: 10.1136/bcr-2016-218514.

PMID:
28710301
19.

Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.

Fujita N, Koie T, Ohyama C, Tanaka Y, Soma O, Matsumoto T, Yamamoto H, Imai A, Tobisawa Y, Yoneyama T, Hatakeyama S, Hashimoto Y.

Int J Clin Oncol. 2017 Dec;22(6):1087-1093. doi: 10.1007/s10147-017-1160-8. Epub 2017 Jul 5.

PMID:
28681153
20.

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM.

Endocr Relat Cancer. 2017 Aug;24(8):393-404. doi: 10.1530/ERC-17-0107. Epub 2017 Jun 29.

Supplemental Content

Loading ...
Support Center